Biopharma R&D Information & Custom Report Preparation

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and prepare tailor-made custom reports on a fee-for-service basis. Our products and subscription services are commercialized via our online store www.lamerie.com and via selected Resellers.

Latest Products

May of 2022
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities
€ 400.00
May of 2022
Claudin 6: A target opportunity to develop effector-enhanced drug modalities
€ 500.00
March of 2022
2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
€ 100.00
March of 2022
Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing
€ 2450.00

Blog

Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review

May 20, 2022

BARCELONA, Spain I May 20, 2022 I La Merie Publishing released today its newest report entitled “Cadherin 17: A target opportunity to develop effector-enhanced drug modalities”. This report describes and analyzes cadherin 17 as a target opportunity for development of

Targeted Protein Degradation (TPD) by proteasomal PROTACs & molecular glues, lysosomal LYTACs and autophagic AUTOTACs or ATTECs provides plenty of opportunities to drug undruggable targets

March 7, 2022

Prodrug antibodies and cytokines generated by masking technologies provide plenty of opportunities for founders, investors and partnerships

October 6, 2021

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: an emerging new technology

July 1, 2021

FREE Newsletter

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Biopharma R&D Information &
Custom Report Preparation

Home

Product of the Month

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Featured Products

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective